

<b>File reference</b>	W18FOI490
<b>Key words</b>	Breast, Lung and Renal Cancer Patient Care
<b>Date of release</b>	21/12/2018
<b>Attachments</b>	No

## Freedom of Information Act Disclosure log - Reply Extract

### You asked

1. **Within your health trust how many metastatic breast cancer patients are currently [within the past 6 months] being treated, with any therapy, surgery or palliative care.**

Please refer to the legal notes\*

2. **Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;**

disodium pamidronate (Aredia)  
ibandronic acid or ibandronate (Bondronat)  
sodium clodronate (Bonefos, Clasteon, Loron)  
zoledronic acid or zoledronate (Zometa)  
denosumab (Xgeva)

Please refer to the legal notes\*

3. **Within your health trust how many breast cancer patients are currently [within the past 6 months] being treated with adjuvant therapy with the following treatments;**

disodium pamidronate (Aredia)  
ibandronic acid or ibandronate (Bondronat)  
sodium clodronate (Bonefos, Clasteon, Loron)  
zoledronic acid or zoledronate (Zometa)

Please refer to the legal notes\*

4. **Within your health trust how many metastatic lung cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.**

Please refer to the legal notes\*

5. **Within your health trust how many lung cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;**

**disodium pamidronate (Aredia)  
ibandronic acid or ibandronate (Bondronat)  
sodium clodronate (Bonefos, Clasteon, Loron)  
zoledronic acid or zoledronate (Zometa)  
denosumab (Xgeva)**

Please refer to the legal notes\*

6. **Within your health trust how many metastatic renal cell cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.**

Please refer to the legal notes\*

7. **Within your health trust how many renal cell carcinoma [RCC] patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;**

**disodium pamidronate (Aredia)  
ibandronic acid or ibandronate (Bondronat)  
sodium clodronate (Bonefos, Clasteon, Loron)  
zoledronic acid or zoledronate (Zometa)  
denosumab (Xgeva)**

Please refer to the legal notes\*

**Legal Notes:** \*University Hospitals Plymouth NHS Trust (UHPT) is confirming in accordance with section 1 (a) of the Act that it does not hold the information requested in any collated format. Individual records of how someone was treated and their conditions would be held in clinical records, but the Trust could not locate, extract and collate such information as requested within the limitations of the Act. Based on a rate of £25 per hour, in accordance with the Fees Regulations, we estimate that it will cost in excess of £450 to locate, retrieve and extract the information you have requested. This sum exceeds the appropriate limit of £450 as defined in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004. It is therefore considered exempt from supply in accordance with section 12(1) of the Act – Request exceeds the appropriate limit by virtue of section 13.-(1)(a) – The Cost of Compliance exceeds the appropriate limit.

**Attachments included:** No